- Cellares and GenomeFrontier Therapeutics will evaluate automated manufacturing of GF-CART01, an investigational CAR-T therapy, using Cellares’ Cell Shuttle platform.
- The collaboration will focus on translating GenomeFrontier’s virus-free manufacturing process to the platform, including transfection using Cellares’ integrated electroporator.
Cellares and GenomeFrontier Therapeutics have entered a partnership to evaluate automated manufacturing for GF-CART01, GenomeFrontier’s investigational CAR-T cell therapy, using Cellares’ Cell Shuttle platform. The collaboration will assess whether GenomeFrontier’s virus-free manufacturing process can be translated to the automated platform.
The evaluation will focus on the transfection unit operation, using Cellares’ proprietary integrated electroporator. According to the companies, the collaboration is Cellares’ first development collaboration in Asia and is intended to support GenomeFrontier’s U.S. clinical initiative as it advances GF-CART01.
GenomeFrontier is developing GF-CART01 for B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, primary mediastinal large B-cell lymphoma and high-grade B-cell lymphoma. The company said it has demonstrated promising clinical data in Taiwan and is actively recruiting for a Phase 1 clinical trial in the United States.
“As we advance GF-CART01, it is important that our manufacturing strategy can support both clinical development and future scale. Our virus-free approach is central to the development of GF-CART01, and this collaboration with Cellares allows us to evaluate how that process can be translated to an automated manufacturing platform as we expand our clinical development in the United States.”
Sareina Wu, PhD, Founder, CEO and Chief Scientific Officer of GenomeFrontier
Through the collaboration, the companies will evaluate the potential to automate GenomeFrontier’s manufacturing process on the Cell Shuttle while maintaining the flexibility required for its virus-free approach. They aim to establish a manufacturing strategy that can improve reliability, reduce manufacturing costs and improve patient access as GenomeFrontier advances GF-CART01.
